123148-66-3

Basic information

• Product Name: 4-Pyridinemethanol,2-methoxy-(9CI)
• Synonyms: 4-Pyridinemethanol,2-methoxy-(9CI);(2-methoxy-4-pyridinyl)methanol;2-Methoxypyridine-4-metha...;2-Methoxypyridine-4-Methanol;2-Methoxypyridin-4-Methanol;2-Methoxy-4-PyridineMethanol;4-PyridineMethanol,2-Methoxy-
• CAS NO: 123148-66-3
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.16
• Product Categories: PYRIDINE
• Mol File: 123148-66-3.mol

Chemical Properties

• Boiling Point: 259.2 °C at 760 mmHg
• Flash Point: 110.6 °C
• Appearance: /
• Density: 1.155 g/cm³
• Vapor Pressure: 0.0067mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Pyridinemethanol,2-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinemethanol,2-methoxy-(9CI)(123148-66-3)
• EPA Substance Registry System: 4-Pyridinemethanol,2-methoxy-(9CI)(123148-66-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 123148-66-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinemethanol,2-methoxy-(9CI) is used as an intermediate in the synthesis of various drugs and pharmaceuticals for its ability to contribute to the development of new medicines and medical treatments. Its unique chemical properties make it a valuable component in the creation of innovative therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Pyridinemethanol,2-methoxy-(9CI) serves as a building block for the production of other chemical compounds. Its versatile structure allows for the formation of a wide range of molecules, enhancing the scope of chemical reactions and the development of novel organic compounds.
Used in Chemical Industry:
4-Pyridinemethanol,2-methoxy-(9CI) plays a crucial role in the chemical industry, where it is utilized in the production of various chemical compounds. Its unique properties and reactivity contribute to the advancement of chemical processes and the creation of new materials with diverse applications.

InChI:InChI=1/C7H9NO2/c1-10-7-4-6(5-9)2-3-8-7/h2-4,9H,5H2,1H3

Upstream product

• 26156-51-4 methyl 2-methoxyisonicotinate 
• 100704-10-7 (2-chloropyridin-4-yl)methanol 
• 124-41-4 sodium methylate 
• 105596-61-0 ethyl 2-methoxy-pyridine-4-carboxylate 
• 22282-72-0 2-hydroxyisonicotinic acid 
• 58481-11-1 methyl 2-chloroisonicotinate 
• 6313-54-8 2-chloroisonicotinic acid, 
• 33252-30-1 2-chloro-4-pyridinenitrile 
• 72716-86-0 4-cyano-2-methoxypyridine 
• 105596-63-2 2-methoxy-isonicotinic acid 
• 754218-84-3 2-methoxypyridine-4-methyl methoxymethyl ether 

Downstream Products

• 72716-87-1 2-methoxypyridine-4-carboxaldehyde 
• 355013-79-5 4-(chloromethyl)-2-methoxypyridine 
• 120277-15-8 4-(bromomethyl)-2-methoxypyridine 
• 1361222-20-9 ethyl N-(diphenylmethylidene)-3-(6-methoxy-4-pyridinyl)alaninate 
• 1361225-28-6 2-((2-methoxy-4-pyridinyl)methyl)piperazine 
• 1361225-30-0 1,1,1,3,3,3-hexafluoro-2-(4-(2-((2-methoxy-4-pyridinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 764708-27-2 2-(2-methoxypyridin-4-yl)ethylamine 
• 1395552-82-5 2-(4-bromo-3-fluorophenyl)-N-[2-(2-methoxypyridin-4-yl)ethyl]-6-methylpyrimidin-4-amine 
• 764708-39-6 C₁₈H₁₆BrFN₄O 
• 764708-28-3 2-(4-bromo-2,5-difluorophenyl)-N-[2-(2-methoxypyridin-4-yl)ethyl]-6-methylpyrimidin-4-amine 
• 1395552-89-2 2-(4-chloro-2,5-difluorophenyl)-N-[2-(2-methoxypyridin-4-yl)ethyl]-6-methylpyrimidin-4-amine 
• 1395552-94-9 2-(4-chloro-2,5-difluorophenyl)-6-ethyl-N-[2-(2-methoxypyridin-4-yl)ethyl]pyrimidin-4-amine 
• 764708-29-4 4-(2-{[2-(4-Bromo-2,5-difluorophenyl)-6-methylpyrimidin-4-yl]amino}ethyl)pyridin-2(1H)-one 
• 795266-61-4 4-(2-{[2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidin-4-yl]amino}ethyl)pyridin-2(1H)-one 

Relevant articles and documents

Discovery of a Class of Potent and Selective Non-competitive Sentrin-Specific Protease 1 Inhibitors

Sentrin-specific proteases (SENPs) are responsible for the maturation of small ubiquitin-like modifiers (SUMOs) and the deconjugation of SUMOs from their substrate proteins. Studies on prostate cancer revealed an overexpression of SENP1, which promotes prostate cancer progression as well as metastasis. Therefore, SENP1 has been identified as a novel drug target against prostate cancer. Herein, we report the discovery and biological evaluation of potent and selective SENP1 inhibitors. A structure-activity relationship (SAR) of the newly identified pyridone scaffold revealed allosteric inhibitors with very attractive in vitro ADMET properties regarding plasma binding and plasma stability for this challenging target. This study also emphasizes the importance of biochemical mode of inhibition studies for de novo designed inhibitors.

Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections

Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated monosulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure-activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.

N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators

The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Compounds Useful as Immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF

The present disclosure relates to a compound of formula I, a pharmaceutical composition thereof and the use thereof as an anti-tumor drug.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists

Novel 4-amino-2-phenylpyrimidine derivatives were synthesized and evaluated as GPR119 agonists. Optimization of the substituents on the phenyl ring at the 2-position and the amino group at the 4-position led to the identification of 3,4-dihalogenated and

PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.